Skip to main content

Judkins Brian C's Form 4/A amendment

Amended

Chemed Corp (CHE) · filed Dec 20, 2024

Accession no.
0000950170-24-138847
Filed
Dec 20, 2024
Trade date
Mar 20, 2024
Filing delay
275 days
Rule 10b5-1 plan
Not checked
Original filed
Mar 20, 2024

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $7.20M. It was filed 275 days after the trade.

This amendment replaces 0000950170-24-035162 (filed Mar 22, 2024).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Judkins Brian CCIK 0001823398Officer (VP and Chief Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 20, 2024Capital StockMOption exerciseAcquired+5,825$413.19+$2,406,831.756,558Direct
Mar 20, 2024Capital StockMOption exerciseAcquired+6,133$471.74+$2,893,181.4212,691Direct
Mar 20, 2024Capital StockSSaleDisposed−11,158$645.00F2−$7,196,9101,533Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 20, 2024Capital StockMOption exerciseDisposed−5,825$413.19−$2,406,831.7529,183Direct
Mar 20, 2024Capital StockMOption exerciseDisposed−6,133$471.74−$2,893,181.4223,050Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Amended filing due to administrative error

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $642.00 to $649.00. The reporting person undertakes to provide to Chemed Corporation, any security holder of Chemed Corporation, or staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

Vesting in three equal annual installments commencing 10/29/2020

F4

Vesting in three equal annual installments commencing 10/29/2021

Read the full filing on SEC EDGAR (opens in a new tab)